All In Biotech

Drug Trial Radar · NCT02758353

The Impact of Sulphadoxine-Pyrimethamine Use At Scale on Newborn Outcomes in Nigeria

Scaling up the Use of Sulphadoxine-Pyrimethamine for the Preventive Treatment of Malaria in Pregnancy: Results and Lessons on Scalability, Costs and Program From Three Local Government Areas in Sokoto State, Nigeria

Last checked: Nov 20, 2026Latest source record: May 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31,493

Actual

Start

Apr 2015

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
JSI Research & Training Institute, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; Federal Ministry of Health, Nigeria
First posted
May 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the feasibility of the scale-up of sulphadoxine- pyrimethamine (SP) for the preventive treatment of malaria in pregnancy in three Local Government Areas (LGAs) in Sokoto State, Nigeria. The scale-up strategy tested included the introduction of community-based distribution of SP in addition to ongoing health facility distribution during antenatal care (ANC) visits. In addition, the study examined for the effect of SP use by participants during pregnancy on the head circumference of live newborns and on the odds of a baby being a stillborn. Finally, the investigators also sought to quantify the costs associated with program scale up SP to deliver at least three doses of SP per participant via a government operated distribution program.

Conditions

  • Malaria
  • Stillbirths

Interventions

  • Community distribution of SPDrug

    SP delivered at both the community and facility level by trained CBHVs in three LGAs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants that got SP coverage among all pregnant womenTime frame: Up to 7 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.